Anavex Life Sciences Corp. (AVXL) Cash Flow Statement
Where AVXL’s cash came from and went, FY2025
September 30, 2025 · U.S. dollars- Cash from operations
- −$39.0M
- Capital expenditures
- $0
- Free cash flow
- −$39.0M
- Returned to shareholders
- —
- Change in cash
- −$29.6M cash at year-end $102.6M
Drawn to scale: where the cash came from and how it was used. Hover for values.
AVXL operating cash flow, capex and free cash flow
AVXL cash flow trends, FY2016–FY2025
| Metric | Trend | Then | Latest | Change |
|---|---|---|---|---|
| Operating cash flow | −$9.2MFY2016 | −$39.0MFY2025 | — | |
| Capital expenditures | $3,015FY2016 | $0FY2025 | −100.0% | |
| Free cash flow | −$9.2MFY2016 | −$39.0MFY2025 | — | |
| Stock-based compensation | $5.1MFY2016 | $11.5MFY2025 | +9.6%/yr | |
| Dividends paid | $0FY2016 | $0FY2018 | — | |
| Share buybacks (net) | $0FY2016 | $0FY2022 | — |
Change is the average annual growth (CAGR) or the difference between the first and latest year.
AVXL cash flow by activity
AVXL net income vs operating cash flow
Operating cash flow above net income usually means earnings are backed by cash (depreciation and stock-based pay are non-cash expenses).
AVXL cash flow statement
| FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating activities | ||||||||||
| Net income | −$46.4M | −$43.0M | −$47.5M | −$48.0M | −$37.9M | −$26.3M | −$26.3M | −$17.3M | −$13.5M | −$14.7M |
| Depreciation & amortization | — | — | — | — | — | — | — | $0 | $0 | $1,252 |
| Stock-based compensation | $11.5M | $9.4M | $16.4M | $18.4M | $8.2M | $4.9M | $6.4M | $5.5M | $4.1M | $5.1M |
| Change in working capital | −$4.2M | $2.8M | $2.5M | $5.4M | −$706,000 | $116,518 | $1.3M | −$846,674 | $382,808 | $640,068 |
| Other non-cash items | $0 | $0 | $845,000 | $0 | $0 | $0 | $35,375 | $0 | −$75,204 | −$203,712 |
| Cash from operating activities | −$39.0M | −$30.8M | −$27.8M | −$24.2M | −$30.4M | −$21.3M | −$18.5M | −$12.6M | −$9.0M | −$9.2M |
| Investing activities | ||||||||||
| Capital expenditures | $0 | $0 | $0 | −$4 | −$4 | −$4 | $0 | $0 | $0 | −$3,015 |
| Investments (net) | — | — | — | — | — | — | — | — | — | $0 |
| Acquisitions & other investing | — | — | — | — | — | — | — | $0 | $0 | $0 |
| Cash from investing activities | — | — | — | — | — | — | — | $0 | $0 | −$3,015 |
| Financing activities | ||||||||||
| Dividends paid | — | — | — | — | — | — | — | $0 | $0 | $0 |
| Share repurchases & issuance (net) | — | — | — | $21.3M | $153.2M | $28.4M | $17.8M | $8.2M | $27.3M | $3.2M |
| Net borrowing (repayment) | — | — | — | — | — | — | −$50,000 | −$101,133 | — | −$34,759 |
| Shares issued | $9.2M | $11.3M | $27.9M | $21.0M | $153.2M | $28.8M | $17.8M | $8.2M | $0 | $0 |
| Other financing | $236,000 | $691,000 | $1.8M | −$21.0M | −$153.2M | −$28.8M | −$17.8M | −$8.2M | $4 | $0 |
| Cash from financing activities | $9.4M | $12.0M | $29.7M | $21.3M | $153.2M | $28.4M | $17.8M | $8.1M | $27.3M | $3.1M |
| Summary | ||||||||||
| Net change in cash | −$29.6M | −$18.8M | $1.9M | −$3.0M | $122.9M | $7.1M | −$745,008 | −$4.5M | $18.3M | −$6.1M |
| Cash at end of period | $102.6M | $132.2M | $151.0M | $149.2M | $152.1M | $29.2M | $22.2M | $22.9M | $27.4M | $9.2M |
| Free cash flow | −$39.0M | −$30.8M | −$27.8M | −$24.2M | −$30.4M | −$21.3M | −$18.5M | −$12.6M | −$9.0M | −$9.2M |
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Jun '25 | Mar '25 | Dec '24 | Sep '24 | Jun '24 | Mar '24 | Dec '23 | Sep '23 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating activities | ||||||||||||
| Net income | $7.8M | −$5.3M | −$5.7M | −$9.8M | −$13.2M | −$11.2M | −$12.1M | −$11.6M | −$12.2M | −$10.5M | −$8.6M | −$10.1M |
| Stock-based compensation | −$16.8M | $314,000 | $1.1M | $3.7M | $4.3M | $1.4M | $2.1M | $2.0M | $2.5M | $2.7M | $2.3M | $3.2M |
| Change in working capital | $2.6M | $584,000 | −$2.6M | −$2.5M | −$3.5M | $3.9M | −$2.1M | $2.9M | $4.6M | −$3.8M | −$982,000 | $1.1M |
| Other non-cash items | −$7.2M | $0 | $0 | $0 | $0 | $0 | $0 | $59,000 | −$59,000 | $0 | $0 | $500 |
| Cash from operating activities | −$13.5M | −$4.4M | −$7.2M | −$8.6M | −$12.5M | −$5.9M | −$12.1M | −$6.7M | −$5.2M | −$11.7M | −$7.3M | −$5.8M |
| Investing activities | ||||||||||||
| Capital expenditures | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Financing activities | ||||||||||||
| Shares issued | $0 | $107,000 | $36.3M | $9.2M | $0 | $0 | $0 | $0 | $4.1M | $0 | $0 | $1.2M |
| Other financing | $113,000 | $6,000 | $0 | $819,000 | −$2.1M | $852,000 | $708,000 | $89,000 | $444,000 | $7.3M | $59,000 | $868,343 |
| Cash from financing activities | $113,000 | $113,000 | $36.3M | $10.0M | −$2.1M | $852,000 | $708,000 | $89,000 | $4.5M | $7.3M | $59,000 | $2.1M |
| Summary | ||||||||||||
| Net change in cash | −$9.1M | −$131.7M | $29.2M | $1.4M | −$14.6M | −$5.0M | −$11.4M | −$6.6M | −$630,000 | −$4.4M | −$7.3M | −$3.8M |
| Cash at end of period | $118.3M | $131.7M | $131.7M | $102.6M | $101.2M | $115.8M | $120.8M | $132.2M | $138.8M | $139.4M | $143.8M | $151.0M |
| Free cash flow | −$13.5M | −$4.4M | −$7.2M | −$8.6M | −$12.5M | −$5.9M | −$12.1M | −$6.7M | −$5.2M | −$11.7M | −$7.3M | −$5.8M |
| Operating cash flow / net income | −1.73 | — | — | — | — | — | — | — | — | — | — | — |
Negative numbers are cash paid out. Quarterly columns are labeled by the month the quarter ended. Figures in U.S. dollars as reported; data from EODHD.
AVXL cash generation
In fiscal 2025 (ended September 30, 2025), Anavex Life Sciences generated -$39.0 million of cash from operations and spent $0 on capital expenditures, leaving free cash flow of -$39.0 million. Cash and equivalents fell by $29.6 million over the year.
Related: AVXL income statement, AVXL balance sheet. See the AVXL stock overview for the latest quote and news.
AVXL cash flow FAQ
What is Anavex Life Sciences's free cash flow?
Anavex Life Sciences's free cash flow was -$39.0 million in fiscal 2025: -$39.0 million of operating cash flow minus $0 of capital expenditures It was -$30.8 million a year earlier..
How much cash does Anavex Life Sciences generate from operations?
Anavex Life Sciences generated -$39.0 million of cash from operating activities in fiscal 2025.